44 results about "Anti convulsants" patented technology

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

This invention relates to combinations of an atypical antipsychotic, and a GABA modulator, a benzodiazepine, and / or an anticonvulsant drug, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from treatment-resistant anxiety disorders, psychotic disorders or conditions, or mood disorders or conditions.

The present invention relates to improved methods and compositions for treating viral infections. More particularly, the present invention relates to novel compositions comprising an anti-convulsant, such as phenytoin, in combination with multivitamins as an anti-viral composition and methods of use thereof.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

System, method, and test strip for solid phase, electrochemical, quantitative analysis of analytes contained in biological fluid samples. Preliminary to analysis, a test sample solution can be applied to a sample collection pad associated with the solid phase test environment of the test strip. The test sample solution and a test kit reagent are thereby initially contacted, under assay conditions, within this solid phase test environment, and caused to migrate along a fluid pathway therein. Irrespective of the assay format (competitive assay, sandwich assay, etc.), a test kit reagent (e.g. labeled substance) and the analyte of interest (e.g. proteins, hormones or enzymes, small molecules, polysaccharides, antibodies, nucleic acids, drugs, toxins, viruses or virus particles, portions of a cell wall and other compounds which have specific or characteristic markers that permit their identification), either interact with one another to form a complex, or, alternatively, compete with one another for interaction with another test kit reagent, resulting in the concentration of an indicator substance within a delimited area of the solid phase. Thereafter, the delimited area of the test strip is subjected to electrochemical analysis and the results determined by monitoring an electrochemical transition in the form of an indicator, or derivative of the indicator (e.g. indicator species), by potentiostatic or potentiometric quantitative analysis (e.g. anodic stripping voltammetry). This electrochemical transition of the indicator has a characteristic electrical fingerprint that can be measured and which, when compared to a standard, can be correlated with the concentration of the analyte in the sample. This method is suitable for the determination / monitoring of therapeutic range of drugs (anti-convulsants drugs), determination of critical and potentially dangerous levels of endogenous materials which are indicative of disease states (prostate cancer), and numerous other applications presently requiring elaborate and time-consuming clinical laboratory analysis.

A rehabilitation training device with anti-convulsant and anti-thrombotic functions for stroke patients comprises a bed frame, a supporting plate and a control mechanism, wherein the supporting plate consists of a fixed part and a rotating part which are hinged to each other; a head and neck support is arranged at one end of the supporting plate; an electrode plate capable of releasing stimulation pulses is arranged on the outer surface of the head and neck support; and the rotating part can be pushed upwards or return downwards. A push-and-pull rod II is arranged at the tail end of the fixed part, and front-back swinging training of a front section of a sole of a patient can be realized. A forearm fixing plate and a shank fixing plate are arranged on the supporting plate, electrode plates are distributed on the surface of the forearm fixing plate and the surface of the shank fixing plate, and the forearm fixing plate and the shank fixing plate can drive the upper limbs or lower limbs of the patient to finish left-right swinging and front-back flexion and extension movements. By the rehabilitation training device, sitting-up and lying-down training, continuous transformation of functional positions of upper affected limbs and lower affected limbs, anti-convulsant training of front-back swinging of soles of both feet and pulse massaging stimulation of the stroke patient can be implemented automatically, muscle spasm and atrophy of the bedridden stroke patient are avoided effectively, and rapid recovery of the stroke patient is promoted.

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

A compound of general formula I below useful as an anticonvulsant for disorders of the central nervous system: ##STR1## wherein: R.sup.1, R.sup.2, R.sup.3 and R.sup.4 may be the same or different and each represents a hydrogen or halogen atom, or a C.sub.1-9 alkyl, C.sub.3-9 cycloalkyl, cyano, C.sub.1-9 alkoxy or C.sub.6-10 aryloxy group; R.sup.5 represents a hydrogen atom or a C.sub.1-9 alkyl, C.sub.3-9 cycloalkyl or C.sub.6-10 aryl group; and X is oxygen or sulfur; or a pharmaceutically-acceptable salt thereof. The compound may be adimistered orally for treating convulsions in humans or animals.

The present invention relates to improved methods and compositions for treating viral infections and other diseases and conditions that induce a cytokine storm. More particularly, the present invention relates to novel compositions comprising quercitin, and an anti-convulsant, such as phenytoin, in combination with mulivitamins as an anti-viral composition and methods of use thereof.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetics thereof, as neuroprotective agents for the treatment and or prevention of neurological disorders including but not limited to cerebral ischemia or cerebral infarction resulting from a range of phenomena, such as thromboembolic or hemorrhagic stroke, cerebral basospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and as anticonvulsants.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the left stellate ganglion, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering anti-arrhythmic therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of anti-arrhythmic therapy include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenyloin, carbamazepine, valproate, and phenobarbitone.

This invention is designed and intended to provide simple, precise delivery of a variety of medications to mucosal surfaces of a living subject, human or non-human animal, including but not limited to the nasal or rectal mucosa, which sites afford rapid absorption and therefore onset of effect of the thus delivered medication. Such medications include, but are not limited to, anticonvulsants, drugs to treat anaphylactic shock, antidotes for poisoning, and medications which are required urgently where either a parenteral formulation is not available or an i.v. route is difficult. Simplicity and needle free safety of use of the various embodiments of the invention allows its operation by laypersons, school-teachers, nurses, paramedics and non¬medical persons in e.g. the armed service. Modular embodiments of the invention facilitate mixing and matching of delivery systems with different dosages and types of medications.

The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents, antidepressants, anti-panic agents, antipsychotic agents, bipolar agents, psychostimulants to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions such as stress disorders, anxiety disorders and depressive disorders.

Novel three-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided. Three-component formulations of the invention comprise biologically active forms of at least one neurosteroid, at least one anti-epileptic or anticonvulsant, and at least one lithium-containing or lithium-related compound. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by neurotrauma. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating neurological trauma, such as those caused by sports injuries, chemical weapons, vehicle collisions and improvised explosive devices in combat.

The invention discloses an orally-taken traditional Chinese medicine composition for treating fibromyalgia syndrome. The traditional Chinese medicine composition is prepared from the following material medicines: herba epimedii, rhizoma curculiginis, prepared rehmannia root, eclipta, obscured homalomena rhizome, pyrola, radix curcuma, rhizoma drynariae, corydalis amabilis, rhizoma smilacis glabrae, liquidambar formosana hance and long-noded pit viper. Compared with the common antidepressant, muscle relaxant, anticonvulsive drugs, and the like, the orally-taken traditional Chinese medicine composition for treating fibromyalgia syndrome has the advantages of positive curative effect, small side effect, high compliance of a patient and the like.

Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided. A polymorph Form II:

(S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid or (S)-pregabalin is an anticonvulsive drug. In addition to its use as an anticonvulsive agent, pregabalin has also been indicated as a medicament in the treatment of anxiety, neuropathic pain and pain in patients with fibromyalgia. Provided herein are thioester intermediates in the synthesis of and processes for the synthesis of 3-(aminomethyl)-5-methyl-hexanoic acid in the (R) or (S) configuration.

Pharmaceutical compositions are disclosed for the treatment of acute, chronic and / or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and / or neuropathic pain and migraine in a mammal including a human is also disclosed.

The invention discloses a tradtional Chinese medicine composition for treating female fibromyalgia syndromes. The tradtional Chinese medicine composition is prepared from the following raw materials: fructus broussonetiae, mulberry, tortoise shell, dogwood, cortex cinnamomi, fructus citri, flos rosae rugosae, tribulus terrestris, valerian, nacre mother of pearl, platycodon grandiflorum, fevervine, rhizoma gastrodiae, herba aristolochiae and tamarix chinensis. The tradtional Chinese medicine composition for treating female fibromyalgia syndromes correspond with the female physiological characteristics; compared with the frequently-used antidepressant, muscle relaxant and anticonvulsant, the pharmaceutical composition has the advantages of being definite in curative effect, small in side effect and high in patient compliance; and therefore, the tradtional Chinese medicine composition is a dedicated drug for treating female fibromyalgia syndromes.

The present invention provides an improved process for the preparation of 1,2-Benzisoxazole-3-methanesulphonamide (Zonisamide), an anti-epileptic agent having anti-convulsant and anti-neurotoxic effects. In another aspect, the invention provides a key intermediate, 1,2-benzisoxazole-3-methane sodium sulfonate (BOS-Na:NaCl), isolated as a crystalline sodium chloride associated compound. The BOS-Na:NaCl isolated is directly converted to Zonisamide using a controlled molar ratio of chlorosulfonic acid to avoid conversion to the disulfonated side products.

The present invention generally relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogues and mimetics thereof, as neuroprotective agents for the treatment and or prevention of cognitive impairment and neurological disorders including but not limited to cerebral ischemic or cerebral infarction, status epilepticus, perinatal asphyxia, anoxia, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and as anticonvulsants. The present invention also generally provides manufacturing methods to prepare of dosage forms. The present invention further generally relates to the use of cyclic Prolyl Glycine and analogues and mimetics thereof, as neuroprotective and neuro-regenerating agents for the treatment and or prevention of depression and other psychological disorders.

The present invention relates to a crystalline form of a compound of formula (I) or formula (Ia), salts of the compound of formula (Ia) and crystal forms thereof, preparation methods thereof, pharmaceutical compositions comprising the same, and use thereof in the preparation of sedation, hypnosis, anxiolytic, muscle-relaxation or anticonvulsant medicines.